HK Stock Market Move | The concept of innovative drugs is becoming stronger, and biopharmaceuticals have for the first time entered the "emerging pillar industry." BD is expected to be driven by both performance and performance.

The concept of innovative drugs strengthened in the early session, as of press time, HUTCHMED (00013) rose by 9.02% to 22.96 Hong Kong dollars; 3SBIO (01530) rose by 8.41% to 21.4 Hong Kong dollars; Jiangsu Hengrui Pharmaceuticals (01276) rose by 5.45% to 65.75 Hong Kong dollars; INNOVENT BIO (01801) rose by 5.42% to 82.7 Hong Kong dollars; KEYMED BIO-B (02162) rose by 5% to 50.4 Hong Kong dollars. On the news front, in this year's national two sessions government work report, biomedicine was explicitly listed as a "new emerging pillar industry" at the national level, alongside industries such as integrated circuits, aerospace, and the low-altitude economy. This is the first time in the government work report that the development of the biomedicine industry has been proposed as a pillar industry, indicating an important policy signal to accelerate industry upgrading. Southwest believes that multiple companies announcing cooperation agreements verifies the research and development strength of these companies. The total amount of BD in the first two months of 2026 has exceeded 50 billion US dollars, close to 40% of the full-year total for the past 25 years, with advance payments exceeding 3 billion US dollars, more than 40% of the past 25 years, and the fundamentals of the innovative drug sector continue to improve. BOCOM INTL points out that various companies' performance forecasts will be released this week, and it is recommended to continue to pay attention to companies with financial performance exceeding expectations and clear profit paths, as their performance realization is expected to catalyze the sector's market.